M 613 (Levetiracetam 250 mg)
Pill imprint M 613 has been identified as Levetiracetam 250 mg.
Levetiracetam is used in the treatment of seizures; epilepsy; bipolar disorder; neuralgia; new daily persistent headache (and more), and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- M 613
- 250 mg
- 10.00 mm
- Prescription only
- Drug Class:
- Pyrrolidine anticonvulsants
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- silicon dioxide
sodium lauryl sulfate
|NDC Code||Manufacturer / Repackager|
|51079-0820||UDL Laboratories Inc|
|35356-0429||Lake Erie Medical and Surgical Supply (repackager)|
Note: Inactive ingredients may vary.
More about levetiracetam
- Levetiracetam extended-release tablets
- Levetiracetam solution
- Levetiracetam tablets
- Levetiracetam (Advanced Reading)
- Levetiracetam Intravenous (Advanced Reading)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.